Off-label and Administrative Criteria

Diagnosis considered for coverage:
  • Food and Drug Administration (FDA)-approved indication
  • Off-label non-FDA approved indication
Coverage Criteria:

For drugs without criteria approved by the WHA P&T Committee:

  • Prescribed medication is being used for a Food and Drug Administration (FDA) approved indication, AND
  • All components of the FDA approved indication are met (e.g., concomitant use, previous therapy requirements, age limitations, testing requirements, etc.), AND
  • Patient meets one of the following:
    • Dose requested does not exceed FDA approved maximum dose for the indication, OR
    • Dose requested is appropriate for the patient’s age or weight

For diagnosis of off-label non-FDA approved indication(s):

  • The drug has been approved as safe and effective by the FDA for at least one indication, AND
  • Preferred drugs for the condition have failed to achieve therapeutic goals, are contraindicated, or caused unacceptable side effects, AND
  • The drug is prescribed by a participating (PAR) provider for a life-threatening condition, or a chronic and seriously debilitating condition, for which no other drug or therapy exists, AND
  • Patient meets one of the following: 
    • Diagnosis is supported as a use in American Hospital Formulary Service Drug Information (AHFS DI), OR
    • Diagnosis is supported as a use in the National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a Category of Evidence and Consensus of 1, 2A, or 2B, OR
    • Diagnosis is supported in the FDA Uses/Non-FDA Uses section in DRUGDEX Evaluation with a Strength of Recommendation rating of Class I, Class IIa, or Class IIb, OR
    • Diagnosis is supported as an indication in Clinical Pharmacology, OR
    • The use is supported by clinical research in two articles from major peer reviewed medical journals that present data supporting the proposed off-label use as generally safe and effective unless there is clear and convincing contradictory evidence presented in a major peer-reviewed medical journal
Coverage Duration: 
  • Initial: 1 year
  • Reauthorization: 1 year
Additional Information: 
  • Examples of peer-reviewed medical literature:
    • American Journal of Medicine 
    • Annals of Internal Medicine 
    • Annals of Oncology 
    • Annals of Surgical Oncology 
    • Biology of Blood and Marrow Transplantation 
    • Blood 
    • Bone Marrow Transplantation 
    • British Journal of Cancer 
    • British Journal of Hematology 
    • British Medical Journal 
    • Cancer 
    • Clinical Cancer Research 
    • Drugs 
    • European Journal of Cancer (formerly the European Journal of Cancer and Clinical Oncology) 
    • Gynecologic Oncology 
    • International Journal of Radiation, Oncology, Biology, and Physics 
    • The Journal of the American Medical Association 
    • Journal of Clinical Oncology 
    • Journal of the National Cancer Institute 
    • Journal of the National Comprehensive Cancer Network (NCCN) 
    • Journal of Urology 
    • Lancet 
    • Lancet Oncology 
    • Leukemia 
    • The New England Journal of Medicine 
    • Radiation Oncology
Policy Updates:
  • 5/17/2022 – New policy approved by P&T
References:
  • Center for Medicaid & Medicare Services. Medicare Prescription Drug Benefit Manual. Chapter 6 – Part D Drugs and Formulary Requirements. Section 10.6. Available at: https://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovContra/Downloads/Part-D-Benefits-Manual-Chapter-6.pdf. Accessed September 9, 2020. 
  • Center for Medicaid & Medicare Services. Medicare Benefit Policy Manual. Chapter 15 - Covered Medical and Other Health Services. Section 50.4.5. Available at: https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/downloads/bp102c15.pdf. Accessed September 9, 2020. 
  • National Comprehensive Cancer Network Categories of Evidence and Consensus. Available at: https://www.nccn.org/professionals/physician_gls/categories_of_consensus.aspx. Accessed September 9, 2020. 
  • Center for Medicaid & Medicare Services. Medicare Benefit Policy Manual. Wolters Kluwer Clinical Drug Information Lexi-Drugs Compendium Revision Request - CAG-00443O. Available at: https://www.cms.gov/medicare-coverage-database/details/medicare-coverage-document-details.aspx?MCDId=31#decision. Accessed September 9, 2020. 
  • Wolters Kluwer Clinical Drug Information’s Request for CMS evaluation of Lexi-Drugs as a compendium for use in the determination of medically-accepted indications of drugs/biologicals used off-label in anti-cancer chemotherapeutic regimens. Available at: https://www.cms.gov/Medicare/Coverage/CoverageGenInfo/downloads/covdoc31.pdf. Accessed September 9, 2020. 
  • Micromedex Healthcare Series. Recommendation, Evidence, and Efficacy Ratings. https://www.micromedexsolutions.com/micromedex2/librarian/ssl/true/CS/6E0ED9/ND_PR/evidencexpert/ND_P/evidencexpert/DUPLICATIONSHIELDSYNC/8B9F5B/ND_PG/evidencexpert/ND_B/evidencexpert/ND_AppProduct/evidencexpert/ND_T/evidencexpert/PFActionId/evidencexpert.IntermediateToDocumentLink?docId=3198&contentSetId=50. Accessed September 9, 2020.
  • Center for Medicaid & Medicare Services. Medicare Coverage Document. Thomson Micromedex DrugDex ® Compendium Revision Request - CAG-00391. Available at: https://www.cms.gov/medicare-coverage-database/view/medicare-coverage-document.aspx?MCDId=16. Accessed October 4, 2021.

Last review date: May 17, 2022

Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone